Journal
VIRAL IMMUNOLOGY
Volume 30, Issue 8, Pages 601-614Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/vim.2017.0033
Keywords
herpes simplex virus type 2; DNA vaccine; adjuvant IL28B; glycoprotein D; UL25; protective immune response
Categories
Funding
- National Natural Science Foundation of China [31200692]
- Jilin Province Science and Technology Development Plan [20140309007YY]
Ask authors/readers for more resources
Antigen-specific immune responses determine the efficacy of herpes simplex virus type 2 (HSV-2) vaccines. To optimize the immunogenicity of the antigen gD2, we developed the gD2UL25 DNA vaccine encoding HSV-2 glycoprotein D and UL25 gene encoding viral capsid vertex proteins in this study. The gD2 and gD2UL25 DNA vaccines were compared with formalin-inactivated HSV-2 (FI-HSV-2), and results showed a greater protective immune response induced by gD2UL25 than by gD2. Therefore, gD2UL25 was chosen to evaluate further using the IL28B adjuvant. Immunization with gD2UL25/IL28B elicited stronger humoral and T cell immune responses than with gD2UL25 alone. Compared with controls, gD2UL25/IL28B decreased HSV-2 viral loads and induced protective effects against genital tract lesions generated by HSV-2. These findings demonstrated that the prophylactic DNA vaccine gD2UL25 with IL28B adjuvant could enhance the humoral and T cell immune responses, and improve the protective immune response against HSV-2 in female mice compared with FI-HSV-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available